Top

Molecular Cancer

Published in:

Open Access 01-12-2011 | Research

Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer

Authors: Bao-Hong Guo, Yan Feng, Rong Zhang, Li-Hua Xu, Man-Zhi Li, Hsiang-Fu Kung, Li-Bing Song, Mu-Sheng Zeng

Published in: Molecular Cancer | Issue 1/2011

Abstract

Background

B-lymphoma Moloney murine leukemia virus insertion region-1 (Bmi-1) acts as an oncogene in various tumors, and its overexpression correlates with a poor outcome in several human cancers. Ectopic expression of Bmi-1 can induce epithelial-mesenchymal transition (EMT) and enhance the motility and invasiveness of human nasopharyngeal epithelial cells (NPECs), whereas silencing endogenous Bmi-1 expression can reverse EMT and reduce the metastatic potential of nasopharyngeal cancer cells (NPCs). Mouse xenograft studies indicate that coexpression of Bmi-1 and H-Ras in breast cancer cells can induce an aggressive and metastatic phenotype with an unusual occurrence of brain metastasis; although, Bmi-1 overexpression did not result in oncogenic transformation of MCF-10A cells. However, the underlying molecular mechanism of Bmi-1-mediated progression and the metastasis of breast cancer are not fully elucidated at this time.

Results

Bmi-1 expression is more pronouncedly increased in primary cancer tissues compared to matched adjacent non-cancerous tissues. High Bmi-1 expression is correlated with advanced clinicopathologic classifications (T, N, and M) and clinical stages. Furthermore, a high level of Bmi-1 indicates an unfavorable overall survival and serves as a high risk marker for breast cancer. In addition, inverse transcriptional expression levels of Bmi-1 and E-cadherin are detected between the primary cancer tissues and the matched adjacent non-cancerous tissues. Higher Bmi-1 levels are found in the cancer tissue, whereas the paired adjacent non-cancer tissue shows higher E-cadherin levels. Overexpression of Bmi-1 increases the motility and invasive properties of immortalized human mammary epithelial cells, which is concurrent with the increased expression of mesenchymal markers, the decreased expression of epithelial markers, the stabilization of Snail and the dysregulation of the Akt/GSK3β pathway. Consistent with these observations, the repression of Bmi-1 in highly metastatic breast cancer cells remarkably reduces cellular motility, invasion and transformation, as well as tumorigenesis and lung metastases in nude mice. In addition, the repression of Bmi-1 reverses the expression of EMT markers and inhibits the Akt/GSK3β/Snail pathway.

Conclusions

This study demonstrates that Bmi-1 promotes the invasion and metastasis of human breast cancer and predicts poor survival.

Available only for authorised users

Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74 10.3322/canjclin.55.2.74

Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 1989, 63 (1): 181-7. 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-HCrossRefPubMed

Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. The New England journal of medicine. 2000, 342 (8): 525-33. 10.1056/NEJM200002243420801 10.1056/NEJM200002243420801CrossRefPubMed

Zhang L, Sullivan P, Suyama J, Marchetti D: Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res. 2010, 8 (2): 278-90. 10.1158/1541-7786.MCR-09-0375 10.1158/1541-7786.MCR-09-0375CrossRefPubMed

Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S: MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA. 2010, 107 (8): 3698-703. 10.1073/pnas.0914203107PubMedCentralCrossRefPubMed

Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco MM, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S: HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA. 2010, 107 (3): 1100-5. 10.1073/pnas.0912710107PubMedCentralCrossRefPubMed

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-52. 10.1038/35021093CrossRefPubMed

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365 (9460): 671-9.CrossRefPubMed

Kallioniemi OP, Wagner U, Kononen J, Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001, 10 (7): 657-62. 10.1093/hmg/10.7.657CrossRefPubMed

10.

Bracken AP, Helin K: Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer. 2009, 9 (11): 773-84. 10.1038/nrc2736CrossRefPubMed

11.

Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM: Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991, 65 (5): 753-63. 10.1016/0092-8674(91)90383-ACrossRefPubMed

12.

van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A: Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991, 65 (5): 737-52. 10.1016/0092-8674(91)90382-9CrossRefPubMed

13.

Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer research. 2002, 62 (16): 4736-45.PubMed

14.

Lessard J, Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003, 423 (6937): 255-60. 10.1038/nature01572CrossRefPubMed

15.

Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004, 13 (5): 383-8. 10.1016/j.breast.2004.02.010CrossRefPubMed

16.

Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005, 115 (6): 1503-21. 10.1172/JCI23412PubMedCentralCrossRefPubMed

17.

Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, Lorenzo Y, Hurtado A, Sánchez A, Bonilla F: Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. 2007, 9 (4): R55- 10.1186/bcr1760PubMedCentralCrossRefPubMed

18.

Nalwoga H, Arnes JB, Wabinga H, Akslen LA: Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer. 2010, 102 (2): 369-75. 10.1038/sj.bjc.6605488PubMedCentralCrossRefPubMed

19.

Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK, Lee SJ, Kong G, Lee JE, Kim JS, Kim JH, Yang JH, Nam SJ: Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast cancer research and treatment. 2009, 113 (1): 83-93. 10.1007/s10549-008-9909-4CrossRefPubMed

20.

Saeki M, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers. Int J Oncol. 2009, 35 (3): 511-5.PubMed

21.

Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66 (12): 6225-32. 10.1158/0008-5472.CAN-06-0094CrossRefPubMed

22.

Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL, Peng ZH: Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 2009

23.

Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS, Huang KH: Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol. 2008, 97 (3): 267-72. 10.1002/jso.20934CrossRefPubMed

24.

Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP, Guo WJ: BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer. 2010, 9 (1): 40- 10.1186/1476-4598-9-40PubMedCentralCrossRefPubMed

25.

Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C, Storz M, Seifert B, Marino S, Schraml P, Dummer R, Moch H: Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer. 2007, 121 (8): 1764-70. 10.1002/ijc.22891CrossRefPubMed

26.

Jiang Y, Su B, Meng X, Liu C, Liu B, Liu D, Fan Y, Yang H: Effect of siRNA-mediated silencing of Bmi-1 gene expression on HeLa cells. Cancer Sci. 101 (2): 379-86.

27.

Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, Band V, Band H, Shi QH, Zeng YX, Zeng MS: The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009, 119 (12): 3626-36. 10.1172/JCI39374PubMedCentralCrossRefPubMed

28.

Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE: BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene. 2009, 28 (34): 3022-32. 10.1038/onc.2009.165PubMedCentralCrossRefPubMed

29.

Langley RR, Fidler IJ: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007, 28 (3): 297-321. 10.1210/er.2006-0027CrossRefPubMed

30.

Sleeman JP: The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent results in cancer research Fortschritte der Krebsforschung. 2000, 157: 55-81.CrossRefPubMed

31.

Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nature reviews. 2004, 4 (6): 448-56. 10.1038/nrc1370PubMed

32.

Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nature reviews. 2002, 2 (6): 442-54. 10.1038/nrc822PubMed

33.

Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002, 3 (3): 155-66. 10.1038/nrm757CrossRefPubMed

34.

Behrens J, Lowrick O, Klein-Hitpass L, Birchmeier W: The E-cadherin promoter: functional analysis of a G.C-rich region and an epithelial cell-specific palindromic regulatory element. Proceedings of the National Academy of Sciences of the USA. 1991, 88 (24): 11495-9. 10.1073/pnas.88.24.11495PubMedCentralCrossRefPubMed

35.

Hajra KM, Ji X, Fearon ER: Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene. 1999, 18 (51): 7274-9. 10.1038/sj.onc.1203336CrossRefPubMed

36.

Giroldi LA, Bringuier PP, de Weijert M, Jansen C, van Bokhoven A, Schalken JA: Role of E boxes in the repression of E-cadherin expression. Biochemical and biophysical research communications. 1997, 241 (2): 453-8. 10.1006/bbrc.1997.7831CrossRefPubMed

37.

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2 (2): 84-9. 10.1038/35000034CrossRefPubMed

38.

Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000, 2 (2): 76-83. 10.1038/35000025CrossRefPubMed

39.

Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004, 6 (10): 931-40. 10.1038/ncb1173CrossRefPubMed

40.

Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA: Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002, 21 (20): 3241-6. 10.1038/sj.onc.1205416CrossRefPubMed

41.

Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY: Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene. 2001, 20 (29): 3814-23. 10.1038/sj.onc.1204505CrossRefPubMed

42.

Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P: Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 2006, 12 (18): 5395-402. 10.1158/1078-0432.CCR-06-0478CrossRefPubMed

43.

Takkunen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A, Virtanen I: Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. J Histochem Cytochem. 2006, 54 (11): 1263-75. 10.1369/jhc.6A6958.2006CrossRefPubMed

44.

Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL: The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest. 2009, 119 (9): 2678-90. 10.1172/JCI37815PubMedCentralCrossRefPubMed

45.

Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009, 15 (5): 402-15. 10.1016/j.ccr.2009.03.017CrossRefPubMed

46.

Tryndyak VP, Beland FA, Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 2010, 126 (11): 2575-83.PubMed

47.

Cowell JK, LaDuca J, Rossi MR, Burkhardt T, Nowak NJ, Matsui S: Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. Cancer genetics and cytogenetics. 2005, 163 (1): 23-9. 10.1016/j.cancergencyto.2005.04.019CrossRefPubMed

48.

Cailleau R, Olive M, Cruciger QV: Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 1978, 14 (11): 911-5. 10.1007/BF02616120CrossRefPubMed

49.

Kremer M, Quintanilla-Martinez L, Fuchs M, Gamboa-Dominguez A, Haye S, Kalthoff H, Rosivatz E, Hermannstädter C, Busch R, Höfler H, Luber B: Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis. Carcinogenesis. 2003, 24 (12): 1879-86. 10.1093/carcin/bgg148CrossRefPubMed

50.

Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, Dimri GP: Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 2007, 67 (11): 5083-9. 10.1158/0008-5472.CAN-06-4368PubMedCentralCrossRefPubMed

51.

Guo WJ, Datta S, Band V, Dimri GP: Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Molecular biology of the cell. 2007, 18 (2): 536-46. 10.1091/mbc.E06-05-0447PubMedCentralCrossRefPubMed

52.

Gong Y, Wang X, Liu J, Shi L, Yin B, Peng X, Qiang B, Yuan J: NSPc1, a mainly nuclear localized protein of novel PcG family members, has a transcription repression activity related to its PKC phosphorylation site at S183. FEBS letters. 2005, 579 (1): 115-21. 10.1016/j.febslet.2004.11.056CrossRefPubMed

53.

Noguchi K, Shiurba R, Higashinakagawa T: Nuclear translocation of mouse polycomb m33 protein in regenerating liver. Biochemical and biophysical research communications. 2002, 291 (3): 508-15. 10.1006/bbrc.2002.6480CrossRefPubMed

54.

Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M: Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes & development. 1997, 11 (2): 226-40.CrossRef

55.

Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, Kajiguchi T, Seto M, Kohno A, Kitamura K, Itoh Y, Asou N, Hamajima N, Emi N, Naoe T: BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005, 82 (1): 42-7. 10.1532/IJH97.05013CrossRefPubMed

56.

Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A: Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood. 2006, 107 (1): 305-8. 10.1182/blood-2005-06-2393CrossRefPubMed

57.

Breuer RH, Snijders PJ, Sutedja GT, Sewalt RG, Otte AP, Postmus PE, Meijer CJ, Raaphorst FM, Smit EF: Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer. 2005, 48 (3): 299-306. 10.1016/j.lungcan.2004.11.026CrossRefPubMed

58.

Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004, 203 (2): 217-24. 10.1016/j.canlet.2003.07.009CrossRefPubMed

59.

Silva J, Garcia JM, Pena C, Garcia V, Dominguez G, Suarez D, Camacho FI, Espinosa R, Provencio M, España P, Bonilla F: Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res. 2006, 12 (23): 6929-36. 10.1158/1078-0432.CCR-06-0788CrossRefPubMed

60.

Miller WR: Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. The Journal of steroid biochemistry and molecular biology. J Steroid Biochem Mol Biol. 2010, 118 (4-5): 273-6. 10.1016/j.jsbmb.2009.10.005CrossRefPubMed

61.

Baumann CK, Castiglione-Gertsch M: Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva ginecologica. 2009, 61 (6): 517-39.PubMed

62.

Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360 (8): 790-800. 10.1056/NEJMra0801289CrossRefPubMed

63.

Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW: Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst. 2000, 92 (21): 1717-30. 10.1093/jnci/92.21.1717CrossRefPubMed

64.

Leuschner C, Enright FM, Gawronska B, Hansel W: Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast cancer research and treatment. 2003, 78 (1): 17-27. 10.1023/A:1022169525521CrossRefPubMed

65.

Price JE, Polyzos A, Zhang RD, Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer research. 1990, 50 (3): 717-21.PubMed

66.

Goldson TM, Vielhauer G, Staub E, Miller S, Shim H, Hagedorn CH: Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells. Molecular carcinogenesis. 2007, 46 (1): 71-84. 10.1002/mc.20276CrossRefPubMed

67.

Grunert S, Jechlinger M, Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003, 4 (8): 657-65. 10.1038/nrm1175CrossRefPubMed

68.

Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T, Schreiber M, Jechlinger M, Beug H: ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 2006, 10 (3): 227-39. 10.1016/j.ccr.2006.07.020CrossRefPubMed

69.

Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, Seruca R, Schmitt FC, Paredes J: Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene. 2009, 29 (3): 392-402. 10.1038/onc.2009.338CrossRefPubMed

70.

Denk C, Hulsken J, Schwarz E: Reduced gene expression of E-cadherin and associated catenins in human cervical carcinoma cell lines. Cancer letters. 1997, 120 (2): 185-93. 10.1016/S0304-3835(97)00308-XCrossRefPubMed

71.

Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature reviews. 2004, 4 (2): 118-32. 10.1038/nrc1276PubMed

72.

Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. The Journal of clinical investigation. 2004, 114 (5): 720-8.PubMedCentralCrossRefPubMed

73.

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004, 117 (7): 927-39. 10.1016/j.cell.2004.06.006CrossRefPubMed

74.

Reichmann E, Schwarz H, Deiner EM, Leitner I, Eilers M, Berger J, Busslinger M, Beug H: Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell. 1992, 71 (7): 1103-16. 10.1016/S0092-8674(05)80060-1CrossRefPubMed

75.

Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer research. 2003, 63 (9): 2172-8.PubMed

76.

Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB: N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer research. 2007, 67 (7): 3106-16. 10.1158/0008-5472.CAN-06-3401CrossRefPubMed

77.

Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR: Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. The Journal of pathology. 1993, 169 (2): 245-50. 10.1002/path.1711690211CrossRefPubMed

78.

Kowalski PJ, Rubin MA, Kleer CG: E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003, 5 (6): R217-22. 10.1186/bcr651PubMedCentralCrossRefPubMed

79.

Bukholm IK, Nesland JM, Borresen-Dale AL: Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. The Journal of pathology. 2000, 190 (1): 15-9. 10.1002/(SICI)1096-9896(200001)190:1<15::AID-PATH489>3.0.CO;2-LCrossRefPubMed

80.

Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML: Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer research. 2001, 61 (2): 489-92.PubMed

81.

Altomare DA, Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005, 24 (50): 7455-64. 10.1038/sj.onc.1209085CrossRefPubMed

82.

Bernards R, Weinberg RA: A progression puzzle. Nature. 2002, 418 (6900): 823- 10.1038/418823aCrossRefPubMed

83.

Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K: Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol. 2008, 61 (2): 197-203. 10.1136/jcp.2006.040378CrossRefPubMed

84.

Dimri GP, Itahana K, Acosta M, Campisi J: Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Molecular and cellular biology. 2000, 20 (1): 273-85. 10.1128/MCB.20.1.273-285.2000PubMedCentralCrossRefPubMed

85.

Chung H, Jung JY, Cho SD, Hong KA, Kim HJ, Shin DH, Kim H, Kim HO, Shin DH, Lee HW, Jeong LS, Kong G: The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers. Mol Cancer Ther. 2006, 5 (3): 685-92. 10.1158/1535-7163.MCT-05-0245CrossRefPubMed

86.

Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF: Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and cellular biology. 2004, 24 (9): 3992-4003. 10.1128/MCB.24.9.3992-4003.2004PubMedCentralCrossRefPubMed

Title: Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer
Authors: Bao-Hong Guo
Yan Feng
Rong Zhang
Li-Hua Xu
Man-Zhi Li
Hsiang-Fu Kung
Li-Bing Song
Mu-Sheng Zeng
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-10-10

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein

New Topoisomerase I mutations are associated with resistance to camptothecin

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study

The HPV-16 E7 oncoprotein induces centriole multiplication through deregulation of Polo-like kinase 4 expression

Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach

Keynote webinar | Spotlight on antibody–drug conjugates in cancer